Prevalence of myocardial infarction polymorphisms in Afyonkarahisar, Western Turkey

Molecular Biology Reports

Volumn 39, Issue 9, 2012, Pages 9257-9264

  Onrat, Serap Tutgun ^a,b   Akci, Önder ^a   Söylemez, Zafer ^a   Onrat, Ersel ^a   Avşar, Alaettin ^a  

^a AFYON KOCATEPE UNIVERSITY   (Turkey)

^b AFYON KOCATEPE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Coronary artery disease; CVD strip assay; Genetic polymorphisms; Myocardial infarction

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; DIPEPTIDYL CARBOXYPEPTIDASE; FIBRINOGEN; METHYLENETETRAHYDROFOLIC ACID; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; THROMBOCYTE ANTIGEN;

ACE GENE; ADULT; APOB GENE; APOE GENE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; ENVIRONMENTAL FACTOR; FEMALE; FV GENE; FXIII GENE; GENE; GENE AMPLIFICATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HETEROZYGOSITY; HOMOZYGOSITY; HPA 1 GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; MTHFR GENE; PAI 1 GENE; TURKEY (REPUBLIC);

ADULT; ALLELES; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMORPHISM, GENETIC; PREVALENCE; RISK FACTORS; TURKEY;

EID: 84865127734     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-012-1799-1     Document Type: Article

References (43)

1. Goldman L, Ausiello D (2004) Cecil textbook of medicine, 22nd edn. Elsevier, Amsterdam, p 975, 400-424, 2281-2298
2. Lusis AJ (2000) Atherosclerosis. Nature 407:233-241
3. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S et al (2003) From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation 108:1664-1672 (Pubitemid 37243650)
4. Eitzman DT, Westrick RJ, Shen Y, Bodary PF, Gu S et al (2005) Homozygosity for factor V Leiden leads to enhanced thrombosis and atherosclerosis in mice. Circulation 111:1822-1825 (Pubitemid 40525148)
5. Lentz SR (2005) Another lesson from the factor V Leiden mouse: thrombin generation drives arterial disease. Circulation 111:1733-1734 (Pubitemid 40525135)
6. Rosenberg RD, Aird WC (1999) Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med 340:1555-1564
7. Voetsch B, Loscalzo J (2004) Genetic determinants of arterial thrombosis. Arterioscler Thromb Vasc Biol 24:216-229 (Pubitemid 38197572)
8. Watkins H, Farrall M (2006) Genetic susceptibility to coronary artery disease: from promise to progress. Nat Rev Genet 7:163-173 (Pubitemid 43361528)
9. Ye Z, Liu EH, Higgins JP, Keavney BD, Lowe GD et al (2006) Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet 367:651-658 (Pubitemid 43289155)
10. Ajjan R, Grant PJ (2006) Coagulation and atherothrombotic disease. Atherosclerosis 186:240-259
11. Lane DA, Grant PJ (2000) Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 95:1517-1532 (Pubitemid 30120809)
12. Wang Q (2005) Molecular genetics of coronary artery disease. Curr Opin Cardiol 20:182-188. doi: 10.1097/01.hco.0000160373.77190.f1 (Pubitemid 40704874)
13. Mayer B, Erdmann J, Schunkert H (2007) Genetics and heritability of coronary artery disease and myocardial infarction. Clin Res Cardiol 96:1-7. doi: 10.1007/s00392-006-0447-y (Pubitemid 46175364)
14. Hamsten A, de Faire U, Walldius G (1987) Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 2:3-9 (Pubitemid 17083665)
15. Brown NJ, Agirbasli MA, Williams GH, Litchfield WR, Vaughan DE (1998) Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension 32:965-971 (Pubitemid 29001421)
16. Larsson PT, Wiman B, Olsson G, Angelin B, Hjemdahl P (1990) Influence of metoprolol treatment on sympatho-adrenal activation of fibrinolysis. Thromb Haemost 63:482-487 (Pubitemid 20214730)
17. Vulin AI, Stanley FM (2004) Oxidative stress activates the plasminogen activator inhibitor type 1 (PAI-1) promoter through an AP-1 response element and cooperates with insulin for additive effects on PAI-1 transcription. J Biol Chem 279:25172-25178 (Pubitemid 38756767)
18. Sawdey MS, Loskutoff DJ (1991) Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-a, and transforming growth factor-h. J Clin Invest 88:1346-1353
19. Kohler HP, Stickland MH, Ossei-Gerning N et al (1998) Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb Haemost 79:8-13 (Pubitemid 28037047)
20. Wartiovaara U, Perola M, Mikkola H et al (1999) Association of FXIII Val34Leu with decreased risk of myocardial infarction in Finnish males. Atherosclerosis 142:295-300 (Pubitemid 29059487)
21. McCormack LJ, Kain K, Catto AJ et al (1998) Prevalence of FXIII V34L in populations with different cardiovascular risk. Thromb Haemost 80:523-524 (Pubitemid 28438756)
22. Franco RF, Reitsma PH, Lourenco D et al (1999) Factor XIII Val34Leu is a genetic factor involved in the aetiology of venous thrombosis. Thromb Haemost 81:676-679 (Pubitemid 29216548)
23. Gemmati D, Serino ML, Ongaro A et al (2001) A common mutation in the gene for coagulation factor XIII-A (VAL34Leu): a risk factor for primary intracerebral hemorrhage is protective against atherothrombotic diseases. Am J Hematol 67:183-188 (Pubitemid 32538617)
24. Reiner AP, Frank MB, Schwartz SM (2002) Coagulation factor XIII polymorphisms and the risk of myocardial infarction and ischaemic stroke in young women. Br J Haematol 116:376-382 (Pubitemid 34155511)
25. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM (1993) The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 268:10739-10745 (Pubitemid 23162248)
26. Eriksson P, Kallin B, van t'Hooft FM, Bavhenolm P, Hamsten A (1995) Allelic-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci 92:1851-1855
27. Margaglione M, Cappucci G, Colaizzo D, Giuliani N, Vecchione G, Grandone E, Pennelli O, Di Minno G (1998) The PAI-1 gene locus 4G/5G polymorphism is associated with a family history of coronary artery disease. Arterioscler Thromb Vasc Biol 18:152-156 (Pubitemid 28277590)
28. McGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE (1994) Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 43:104-109
29. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T et al (1996) Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 2:800-803 (Pubitemid 26225097)
30. Lyon CJ, Hsueh WA (2003) Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease. Am J Med 115(Suppl 8A):62S-68S (Pubitemid 37532894)
31. Shinozaki K, Ayajiki K, Nishio Y, Sugaya T, Kashiwagi A, Okamura T (2004) Evidence for a causal role of the renin-angiotensin system in vascular dysfunction associated with insulin resistance. Hypertension 43:255-262 (Pubitemid 38174184)
32. Kluijtmans LAJ, van den Heuvel LPWJ, Boers GHJ, Frosst P, Stevens EMB, van Oost BA, den Heijer M, Trijbels FJM, Rozen R, Blom HJ (1996) Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 58:35-41
33. Morita H, Taguchi J, Kurihara H, Kitaoka M, Kaneda H, Kurihara Y, Maemura K, Shindo T, Minamino T, Ohno M, Yamaoki K, Ogasawara K, Aizawa T, Suzuki S, Yazaki Y (1997) Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation 95:2032-2036 (Pubitemid 27184270)
34. Atherosclerosis, Thrombosis and Vascular Biology Italian Study Group (2003) No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. Circulation 107:1117-1122. doi: 10.1161/01.CIR.0000051465.94572.D0
35. Ardissino D, Mannucci PM, Merlini PA et al (1999) Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood 94:46-51 (Pubitemid 29300133)
36. Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, Culebras A, Degraba TJ, Gorelick PB, Guyton JR, Hart RG, Howard G, Kelly-Hayes M, Nixon JV, Sacco RL; American Heart Association/American Stroke Association Stroke Council; Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; Quality of Care and Outcomes Research Interdisciplinary Working Group; American Academy of Neurology (2006) Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke 37:1583-1633 (erratum in: Stroke 38:207 (2007))
37. Prescott E, Hippe M, Schnohr P, Hein HO, Vestbo J (1998) Smoking and risk of myocardial infarction in women and men: longitudinal population study. Br Med J 316:1043-1047 (Pubitemid 28143100)
38. Wolf PA, D'Agostino RB, Kannel WB, Bonita R, Belanger AJ (1988) Cigarette smoking as a risk factor for stroke. The Framingham study. J Am Med Assoc 259:1025-1029 (Pubitemid 18046850)
39. Mamun AA, Peeters A, Barendregt J, Willekens F, Nusselder W, Bonneux L (2004) Smoking decreases the duration of life lived with and without cardiovascular disease: a life course analysis of the Framingham heart study. Eur Heart J 25:409-415 (Pubitemid 38391523)
40. Li MD, Payne TJ, Ma JZ, Lou XY, Zhang D, Dupont RT, Crews KM, Somes G, Williams NJ, Elston RC (2006) A genome wide search finds major susceptibility loci for nicotine dependence on chromosome 10 in African Americans. Am J Hum Genet 79:745-751 (Pubitemid 44452753)
41. Loukola A, Broms U, Maunu H, Widen E, Heikkila K, Siivola M, Salo A, Pergadia ML, Nyman E, Sammalisto S, Perola M, Agrawal A, Heath AC, Martin NG, Madden PA, Peltonen L, Kaprio J (2007) Linkage of nicotine dependence and smoking behavior on 10q, 7q and 11p in twins with homogeneous genetic background. Pharmacogenom J 8(3):209-219
42. Smith SC (2007) Multiple risk factors for cardiovascular disease and diabetes mellitus. Am J Med 120(3 Suppl1):S3-S11 (review) (Pubitemid 46274577)
43. Peltonen L, Palotie A, Lange K (2006) Use of population isolates for mapping complex traits. Nat Rev Genet 1:182-190 (review)